UOC
FOMX

UBS O'Connor’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

UBS O'Connor’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-76,454
Closed -$274K – 297
2018
Q4 		$274K Sell
76,454
-25,346
-25% -$110K 0.01% 207
2018
Q3 		$583K Buy
+101,800
New +$582K 0.01% 234
2017
Q2 		– Sell
-30,000
Closed -$148K – 519
2017
Q1 		$148K Buy
+30,000
New +$289K ﹤0.01% 382

Other funds holding FOMX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

UBS O'Connor's FOMX Position: Q1 2019 in Review

UBS O'Connor sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2019, closing a stake of 76,454 shares — an estimated $274K sold.

UBS O'Connor first reported a position in FOMX in Q1 2017 and held it in 3 quarters. The position peaked at $583K in Q3 2018. 62 funds tracked by Wall St. Rank hold FOMX as of Q1 2019.

  • UBS O'Connor reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • UBS O'Connor sold 76,454 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2019, an estimated $274K.
  • UBS O'Connor first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2017 and held it in 3 quarters.
  • UBS O'Connor's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $583K in Q3 2018.
  • 62 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2019.

Based on UBS O'Connor's 13F filing for Q1 2019, filed 13 May 2019.